The Adderall shortage that began making headlines in 2022 is still not over. As of early 2026, both immediate-release and extended-release formulations of Adderall remain in active shortage according to the FDA and the American Society of Health-System Pharmacists. While the situation has improved compared to the worst stretches of 2023 and 2024, patients across the country — particularly those prescribed the most common adult doses of 20 mg and 30 mg immediate-release tablets — continue to face empty pharmacy shelves, long wait times, and the stress of not knowing when their medication will be available. For the millions of adults managing ADHD, many of whom also navigate co-occurring cognitive health concerns, this shortage is more than an inconvenience.
It disrupts routines, destabilizes symptom management, and forces difficult conversations with doctors about switching medications. Consider a 58-year-old patient in Ohio who has taken the same Adderall dose for seven years and suddenly cannot fill her prescription at any of the four pharmacies in her town. She is not alone, and the reasons behind her predicament involve a tangle of federal production quotas, manufacturing bottlenecks, and surging demand that no single fix can resolve overnight. This article breaks down why the shortage persists heading into 2026, what the DEA and manufacturers have done (and failed to do), when experts believe supply will catch up with demand, and what patients can do in the meantime to protect their treatment plans.
Table of Contents
- Why Is the Adderall Shortage Still Happening in 2025 and 2026?
- What the DEA Has Done — and Why It Took So Long
- The Demand Side — Why So Many More People Need ADHD Medication
- What Patients Can Do Right Now to Manage the Shortage
- Risks of Going Without — Especially for Older Adults
- How the Shortage Affects Caregivers and Families
- When Will the Adderall Shortage Actually End?
- Conclusion
- Frequently Asked Questions
Why Is the Adderall Shortage Still Happening in 2025 and 2026?
The shortage comes down to a fundamental mismatch between supply and demand, made worse by a regulatory system that was never designed for this level of need. The DEA sets annual Aggregate Production Quotas for controlled substances like amphetamine, and those quotas are based on prior-year sales data — not on actual patient demand or prescription volume. When demand rises faster than the quota formula can account for, manufacturers literally cannot produce enough medication even if they have the capacity and desire to do so. Meanwhile, ADHD diagnoses among both children and adults have climbed sharply over the past five years, driven by greater awareness, reduced stigma around seeking treatment, and the explosion of telehealth services that made evaluation and prescribing more accessible. On the manufacturing side, the picture is no less complicated. Teva Pharmaceuticals, the largest generic Adderall producer in the United States, has experienced intermittent production delays stemming from quality control problems, raw material shortages, and facility capacity limitations. These are not quick fixes.
A pharmaceutical plant cannot simply flip a switch and double output. When one major producer falls behind, the ripple effects hit every pharmacy in the country. The FDA has confirmed that manufacturers reported shortages in 2025 citing increases in product demand, supply chain issues, manufacturing and quality problems, lack of active ingredients, and business decisions. Compare this to a shortage of, say, a common antibiotic. When demand spikes for amoxicillin, multiple manufacturers can ramp up production relatively quickly because it is not a controlled substance. With Adderall, every gram of amphetamine produced must fall within the DEA’s approved quota. Even willing manufacturers hit a legal ceiling. That structural bottleneck is what separates this shortage from ordinary drug supply disruptions and why it has dragged on for years rather than months.
What the DEA Has Done — and Why It Took So Long
In a historic move on October 2, 2025, the DEA increased the Aggregate Production Quota for d-amphetamine — the primary active ingredient in Adderall and its generics — from 21.2 million grams to 26.5 million grams, a roughly 25 percent increase. this was the first time the DEA had ever adjusted the APQ for Adderall and its generics mid-year. In September 2025, the agency also raised the quota for lisdexamfetamine (the active ingredient in Vyvanse) from 32.7 million grams to 39.9 million grams, an increase of about 22 percent. Quotas for methylphenidate, used in Ritalin and Concerta, were also increased. Then on January 5, 2026, the DEA published finalized 2026 APQs with higher production targets reflecting the increased demand. These are meaningful steps, but they come with a critical limitation: raising a production quota does not put pills on pharmacy shelves tomorrow.
Manufacturers need time to source raw materials, schedule production runs, clear quality inspections, and distribute finished products through a supply chain that has its own bottlenecks. Industry analysts have compared it to turning a large ship — the course correction has been made, but the vessel takes a long time to complete the turn. Patients hoping for immediate relief after the October 2025 announcement were largely disappointed, though gradual improvements have been reported in some regions. However, if you are a patient whose specific dosage or formulation is produced by a manufacturer that has not yet ramped up production, the quota increase may not help you for months. The benefits of higher quotas are unevenly distributed across manufacturers, dosage strengths, and geographic regions. A pharmacy in a major metropolitan area with multiple wholesaler relationships may see improvement faster than a rural pharmacy that relies on a single distributor. This uneven recovery is one reason the shortage can feel fully resolved for some patients while remaining acute for others.
The Demand Side — Why So Many More People Need ADHD Medication
The supply problems do not exist in a vacuum. They collide with a genuine and significant increase in the number of people seeking ADHD treatment. Over the past five years, adult ADHD diagnoses in particular have risen sharply. Much of this reflects long-overdue recognition of a condition that was historically dismissed in adults or misattributed to anxiety, depression, or personality traits. The pandemic era accelerated this trend as remote work and disrupted routines unmasked ADHD symptoms that structured office environments had previously compensated for. At the same time, telehealth platforms made it far easier to obtain an evaluation and prescription without the months-long wait for an in-person psychiatry appointment.
For a brain health audience, this intersection matters. Many adults seeking ADHD evaluation for the first time are in their 40s, 50s, or 60s — people who may also be monitoring their cognitive health for early signs of decline. ADHD symptoms like forgetfulness, difficulty concentrating, and trouble completing tasks can overlap with or be mistaken for early cognitive impairment. A proper ADHD diagnosis and treatment plan can meaningfully improve daily functioning and quality of life for these individuals, but only if the prescribed medication is actually obtainable. The rise in demand is not artificial or driven by overprescribing, as some commentators have suggested. The American Journal of Managed Care has highlighted that the stimulant shortage reflects growing challenges in meeting legitimate adult treatment needs. The DEA’s own decision to raise quotas by 22 to 25 percent implicitly acknowledges that prior limits were inadequate for actual patient demand.
What Patients Can Do Right Now to Manage the Shortage
If you or someone you care for cannot fill an Adderall prescription, there are practical steps worth considering — though none are perfect substitutes for a stable medication supply. First, call multiple pharmacies. Availability varies widely not just between cities but between pharmacies in the same zip code. Independent pharmacies sometimes have better luck sourcing controlled substances through different wholesaler networks than large chains do. Some patients have reported success using the FDA’s drug shortage database or tools like Medfinder to check which pharmacies have stock of specific dosages. Second, talk to your prescriber about therapeutic alternatives.
Switching from Adderall IR to an extended-release formulation, or vice versa, may improve your chances if one formulation is more available in your area. Other amphetamine-based medications like Vyvanse (lisdexamfetamine) or Dexedrine (dextroamphetamine) contain similar active ingredients and may be more readily available at a given time, though Vyvanse has faced its own supply constraints. Methylphenidate-based options like Ritalin or Concerta represent a different drug class entirely and may or may not work as well for a given patient, so this tradeoff involves a genuine clinical conversation rather than a simple swap. The key tradeoff to understand is this: switching medications to avoid the shortage may resolve the access problem but introduces a period of adjustment, potential side effects, and uncertainty about efficacy. For someone whose ADHD is well-controlled on a specific Adderall dose, a forced switch can be destabilizing. Weigh this against the harm of going without medication entirely, which for many patients is the worse outcome.
Risks of Going Without — Especially for Older Adults
Abruptly stopping a stimulant medication is not medically dangerous in the way that stopping certain other medications can be, but the functional consequences can be severe. Patients who lose access to their ADHD medication often experience a sharp return of symptoms: difficulty concentrating, impulsivity, disorganization, and fatigue. For older adults, these symptoms can compound existing cognitive vulnerabilities and lead to medication errors with other prescriptions, missed appointments, falls related to inattention, and withdrawal from social activities. There is also a mental health dimension that deserves candid acknowledgment. The anxiety produced by not knowing whether you will be able to fill your prescription next month is itself a source of significant stress.
Some patients report hoarding partial prescriptions, splitting doses to stretch their supply, or seeking medication from unverified sources — all of which carry their own risks. Dose-splitting without medical guidance can result in inconsistent symptom control, and purchasing stimulants outside a pharmacy is both illegal and dangerous given the prevalence of counterfeit pills containing fentanyl. A warning worth emphasizing: if you are an older adult experiencing new or worsening cognitive symptoms and you have recently lost access to your ADHD medication, do not assume the symptoms are simply your ADHD returning. Discuss the changes with your physician. Medication disruptions can unmask or exacerbate other conditions, and a thorough evaluation is always warranted when cognitive function changes.
How the Shortage Affects Caregivers and Families
The Adderall shortage does not only affect the person with the prescription. Family members and caregivers often bear the logistical burden of calling pharmacies, coordinating with prescribers, and managing the emotional fallout when medication is unavailable. In households where a parent with ADHD is also a caregiver for someone with dementia or another cognitive condition, the stakes are compounded.
An unmedicated caregiver may struggle with the executive function demands of managing complex care schedules, medication regimens for their loved one, and the sustained attention required for safe caregiving. One caregiver in Texas described spending three hours every month calling pharmacies across two counties to locate her husband’s Adderall prescription — time she could have spent on his care or her own wellbeing. These are the invisible costs of a drug shortage that statistics about production quotas and manufacturing delays do not capture.
When Will the Adderall Shortage Actually End?
No one can give a firm end date, and anyone who does is guessing. The most credible expert estimates suggest it could take until late 2026 or into 2027 before supply consistently meets demand on a national level. Regional spot shortages at individual pharmacies are expected to persist through at least mid-2026, even as overall production increases.
The DEA’s higher 2026 production quotas and the October 2025 mid-year adjustment are positive signals, but the gap between authorizing more production and seeing it reflected in pharmacy inventory is measured in months, not weeks. Looking ahead, the broader question is whether the regulatory framework governing controlled substance production can adapt to a healthcare landscape where ADHD is increasingly recognized and treated across the lifespan. If production quotas continue to lag behind actual demand by one or two years, shortages will recur. The DEA’s unprecedented mid-year adjustment in 2025 may signal a willingness to be more responsive, but structural reform — such as basing quotas on prescription data rather than sales data — would do more to prevent future shortages than any one-time increase.
Conclusion
The Adderall shortage entering 2026 is a story of demand outpacing a regulatory and manufacturing system that was not built for this moment. DEA quota increases of 22 to 25 percent for key stimulant ingredients are a necessary step, but the lag between policy change and pharmacy availability means patients will continue to face disruptions for months to come. The most affected are those on the most common adult doses — 20 mg and 30 mg immediate-release — and those in areas with fewer pharmacy options.
If you are managing ADHD alongside other cognitive health concerns, the most important thing you can do is maintain an open line of communication with your prescriber, explore backup medication options before your current supply runs out, and resist the temptation to ration or stretch doses without medical guidance. The shortage is real, it is improving, and it is not yet over. Planning ahead and staying informed remain your best tools for navigating it.
Frequently Asked Questions
Is the Adderall shortage officially over?
No. As of early 2026, both immediate-release and extended-release Adderall remain listed in active shortage by the FDA and ASHP. The situation has improved since 2023-2024 but is not fully resolved.
Which Adderall dosages are hardest to find?
The 20 mg and 30 mg immediate-release tablets are the most difficult to locate, as they are the most commonly prescribed adult doses.
Did the DEA do anything to help with the shortage?
Yes. In October 2025, the DEA raised the d-amphetamine production quota by approximately 25 percent — the first mid-year adjustment ever made for this drug. They also increased quotas for lisdexamfetamine and methylphenidate, and published higher 2026 production targets in January 2026.
Can I switch from Adderall to Vyvanse during the shortage?
Possibly, but Vyvanse has also experienced supply constraints. Talk to your prescriber about whether lisdexamfetamine or a methylphenidate-based medication like Ritalin or Concerta might be appropriate. Each involves clinical tradeoffs in terms of efficacy and side effects.
When do experts think the shortage will end?
Most estimates point to late 2026 or 2027 before supply consistently meets demand nationwide. Regional spot shortages may continue through at least mid-2026.
Is it safe to split or ration my Adderall to make it last longer?
Do not adjust your dose without consulting your prescriber. Inconsistent dosing can lead to poor symptom control and may complicate your treatment plan. Your doctor may be able to suggest a temporary alternative or adjusted regimen.
